INCYTE CORP (INCY)
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
📈 **POSITIVE** • Medium confidence analysis (79%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business